echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Cancer is the first innovative drug! Ono Pharmaceuticals filed a listing application for NON-7643 in Japan

    Cancer is the first innovative drug! Ono Pharmaceuticals filed a listing application for NON-7643 in Japan

    • Last Update: 2021-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Ono Pharmaceuticals of Japan recently announced that it has filed a listing application for ONO-7643, a gastric hunger agent (ghrelin) permutation agent used to improve weight loss and anorexia in patients with cancer.
    The application is based on the results of two clinical studies conducted in Japan in patients with cancer erythroid disease: (1) a multi-center, placebo-controlled, randomized, double-blind, parallel group study (ONO-ONO-) in patients with non-small cell lung cancer (NSCLC). 7643-04 Study) ;(2) A multi-center, open-label, non-controlled Phase III study (ONO-7643-05 study) in patients with colorectal, stomach and pancreatic cancers.
    study, anamorelin showed weight gain, muscle mass, and appetite in cancer patients. It is worth mentioning that anamorelin was one of the most important innovations in oncology in 2014 by the judges of the European Association Technology Association (ASCO). If approved, anamorelin is expected to be the first drug to treat cancer.
    cancer is a complex metabolic disorder characterized by weight loss (especially muscle mass loss) and cancer-related anorexia. Cancer can have a significant negative impact on the quality of life and prognosis of patients. To date, no effective treatment has been established.anamorelin molecular structure
    anamorelin is a new, oral, selective gastric hunger agent (ghrelin) permitation agent. Gastric hunger hormone is an endogenemic peptide, mainly secreted by the stomach, combined with its subject, stimulates a variety of ways to positively regulate weight, muscle mass, appetite and metabolism. By simulating stomach hunger hormone secreted by the gastrointestinal tract, anamorelin can improve weight loss and loss of appetite in patients with cancer.
    under a licensing agreement with Helsinn Healthcare SA, a subsidiary of the Swiss Helsinn Group, Ono Pharmaceuticals has exclusive rights to the development and commercialization of Anamorelin in Japan, Korea and Taiwan, China. (Bio Valley)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.